<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444402</url>
  </required_header>
  <id_info>
    <org_study_id>173HPS17013</org_study_id>
    <nct_id>NCT03444402</nct_id>
  </id_info>
  <brief_title>A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, and Three-way Crossover Clinical Trial to Compare Pharmacokinetics and Safety of CKD-381 and D026 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple-dose, and three-way cross over clinical trial to compare
      pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Actual">May 4, 2018</completion_date>
  <primary_completion_date type="Actual">May 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval at steady state)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss(Maximum concentration of drug in plasma at steady state)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss(Time to maximum plasma concentration at steady state)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(Terminal elimination half-life)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R(Accumulation ratio)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F(Apparent Clearance at steady state)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss/F(Apparent Volume of distribution at steady state)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(Maximum concentration of drug in plasma)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast(Area under the plasma drug concentration-time curve from 0 to last)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax(Time to maximum plasma concentration)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(Terminal elimination half-life)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F(Apparent clearance)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F(Apparent volume of distribution)</measure>
    <time_frame>0~24h</time_frame>
    <description>Evaluation PK esomeprazole after single dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-381(formulation I)</intervention_name>
    <description>1 tablet administered before the breakfast during 7 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-381(formulation II)</intervention_name>
    <description>1 tablet administered before the breakfast during 7 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D026(Nexium 40mg)</intervention_name>
    <description>1 tablet administered before the breakfast during 7 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 50 aged in healthy male adult

          2. Body weight more than 55kg

          3. Body Mass Index more than 18.5 and under 25

        Exclusion Criteria:

          1. Have clinically significant disease that hepatobiliary system, kidney, nervous system,
             immune system, respiratory system, endocrine system, hemato-oncology disease,
             cardiovascular system or mental illness, or a history of mental disease.

          2. Have a gastrointestinal disease history that can effect drug absorption or surgery.

          3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the
             history of Esomeprazole, additives or benzimidazole family.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Sang Yu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-381</keyword>
  <keyword>Nexium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

